Future Fund: Breakthrough Header
Future Fund: Breakthrough

Frequently asked questions

General

FF:B is a new £375m UK-wide programme which encourages private investors to co-invest in high-growth, innovative companies. Through the Future Fund: Breakthrough programme, British Patient Capital will make equity co-investments with private sector investors in later stage R&D-intensive UK companies operating in breakthrough technology sectors, such as quantum computing, cleantech, and life sciences. British Patient Capital will construct a portfolio of growth-stage breakthrough technology companies over time.

The fund will not invest in companies looking to develop or employ products with a short time-to-market, recognising that a strong private sector market for investment in these sectors already exists.

The types of companies FF:B is targeting will help accelerate the deployment of breakthrough technologies which have the potential to transform major industries, develop new medicines, support the transition to a net zero economy and strengthen the UK’s position as a science superpower. Due to high research and development costs, breakthrough technology companies typically require more capital than other companies to fuel the later stages of their growth.

FF:B will only invest in funding rounds of at least £30m in size, including FF:B capital. The maximum FF:B share is 30%, meaning that the minimum amount of private sector funding in a potentially eligible round needs to be £21m. FF:B will invest on the same terms as the lead investor.

FF:B is now open for applications from lead investors.

FF:B will be delivered via British Patient Capital, a commercial subsidiary of the British Business Bank.

Applications to FF:B can only be made by a lead investor.

Lead investors can apply to FF:B on the For investors page of this website.

Companies cannot apply directly for FF:B funding. Applications can only be made by investors. Companies can however register for general British Business Bank updates and news on the British Business Bank website.

Budget

None of this funding has been diverted from other Bank schemes.

Company Eligibility Criteria

FF:B targets innovative, R&D-intensive UK companies operating in breakthrough technology sectors, such as quantum computing, cleantech, and life sciences, that have longer lead times to product commercialisation. The fund is focused on areas of the market where there is the greatest need for intervention, to increase the investment round size. Full company level eligibility criteria are listed below.

To be eligible for the scheme, a company must meet all of the following eligibility criteria:

  • The company receiving investment should be UK based (UK incorporated) with significant UK operations (meaning at least half of the company’s overall employment base and half of its research employees are based in the UK).
  • The company must be carrying out R&D activity in the UK by meeting all three of the following criteria:
    • R&D spending (as defined by pre-set accounting rules) must have been at least 10% of total operational cost base on average over the last 3 years or at least 15% in one of the past 3 years.
    • Company is developing defensible intellectual property in the UK which they expect to be the company’s main revenue source.
    • Company intends that 20% or more employees will be carrying out research for at least 3 years from the date of investment, in roles that require a relevant master’s degree or higher.
  • The company must have raised at least £5m of equity investment from third-party investors in previous funding rounds in the last five years prior to Future Fund: Breakthrough investment.
  • The company must be raising a minimum investment round size of £30m

R&D spend is defined for the purpose of FF:B by FRS 102 as “original and planned investigation undertaken with the prospect of gaining new scientific or technical knowledge and understanding”.

The total operational cost base includes both fixed and variable operating costs, i.e. those costs associated with the day to day running of the core business.

We are likely to regard IP as ‘defensible’ where the company is the proprietor of or is the applicant for a patent on an invention and/or where the product or process in question is confidential to the company and is protected as a trade secret and/or is protected by other intellectual property rights belonging to the company.

If subsequent to FF:B’s investment the company develops in such a way that it significantly moves away from the company eligibility criteria, British Patient Capital will have the option to sell its investment and will expect the company to help facilitate that sale.

Yes, FF:B is open to eligible companies across the whole of the UK.

Companies looking to raise capital via FF:B must have a lead investor. The lead investor needs to meet the criteria outlined in Question 16 and be an investor in the proposed funding round. The lead investor can be a new or existing investor in the company.

No, the lead investor does not need to be the largest investor in the syndicate. The lead investor needs to meet the investor criteria outlined in Question 16 and can be a new or existing investor in the company.

Companies raising an investment round with the support of FF:B will require a lead investor to meet one of the three criteria below. The lead investor can be:

  • Any fund managed or advised by an FCA (or equivalent) authorised firm with private sector investment making up greater than 50% of the total fund size and who is currently managing an active fund greater than £100m. The fund must have raised capital from at least three independent LPs (or equivalent) and have a written investment strategy that aligns with the investment strategy of FF:B;
  • Any fund or investment vehicle with an appropriate investment strategy, managed or advised by a fund manager which has applied to and obtained an investment from a member of the British Business Bank group. For example, those supported by British Patient Capital and by the British Business Bank’s Enterprise Capital Funds programme.
  • Other investment vehicles with a minimum of £100m of investment capital, a broad range of independent investors (at least 3), a demonstrable track record and an appropriate investment strategy where these have been approved by FF:B

The lead investor will be required to share an investment paper with BPC setting out the rationale for making the investment. The paper should include information about valuation, the business plan and follow-on funding expectations. The lead investor will also be subject to reputation and customer due diligence (CDD) checks and will be required to share with British Patient Capital any legal and financial due diligence reports prepared on the company.

The lead investor will also be expected to contribute a significant amount to the investment round. This will be assessed by British Patient Capital, by taking into consideration the financial position of the fund and the level of previous investment in the company.

Yes, tax advantaged investors such as EIS/VCTs will be able to invest as part of a syndicate. However, they will not be able to be a lead investor for FF:B purposes.

Yes, corporate VCs will be able to invest as part of a syndicate. They will also be able to be a lead investor for FF:B purposes if they meet one of the criteria set out in Question 16.

Yes, other investors will be able to invest as part of a syndicate. However, for the purposes of FF:B, they can only be a lead investor if they meet one of the criteria set out in Question 16.

There is no limit to the number of investors who can invest in a FF:B funding round, providing the lead investor requirements referenced in Question 16 are satisfied.

Yes, providing they meet one of the three criteria referenced in Question 16, overseas investors can lead FF:B funding rounds.

Relationship with Future Fund

No. Future Fund was set up to support innovative firms suffering due to the Covid-19 pandemic, by offering Convertible Loan Notes. FF:B is not a Covid-19 mitigation measure but is a direct co-investment fund aimed at growth stage innovative, R&D-intensive UK companies seeking larger investments than the Future Fund offered.

No. These are entirely separate and different programmes. Future Fund addressed the immediate funding challenges that innovative, equity backed, UK companies faced due to Covid-19. Whereas Future Fund: Breakthrough focuses on R&D intensive companies and will leverage the existing co-investment capabilities of British Patient Capital, constructing a portfolio of growth-stage breakthrough technology companies over time.

This scheme is not aimed at the original Future Fund cohort. However, these companies may receive funding from FF:B, or other government schemes, should they meet the required eligibility criteria.

No. FF:B is an entirely separate programme targeting R&D intensive scale up companies. It will not prioritise existing Future Fund investee companies.

Investment

An equity investment, with FF:B investing on commercial and no less favourable terms than the lead investor. FF:B will invest up to 30% of a funding round.

It is our expectation that lead investors (meeting the criteria set out above in question 16) will lead the transactions and will be British Patient Capital’s main initial contact point. Lead investors with companies/proposals which meet the company eligibility criteria will be contacted by the investment team. Only proposals/companies introduced by an eligible lead investor will be considered.

An overview of the investment process is outlined below:

a. Assessment of lead investor eligibility. Once an investor has completed the on-line application form and been assessed as potentially eligible, a member of the British Patient Capital team will get in touch with the lead investor to verify their eligibility as a lead investor for FF:B purposes and to discuss any proposed investee company.
b. Introduction of British Patient Capital to the potential investee company by the lead investor. Once the lead investor has been confirmed as eligible, the British Patient Capital investment team will ask the lead investor for an introduction to the investee company.
c. Assessment of investee company and transaction eligibility. The British Patient Capital investment team will review whether the potential investee company and transaction meet the programme’s criteria.
d. Due diligence on investment opportunity. The British Patient Capital investment team will undertake analysis of the potential investee company and its technology. When British Patient Capital has completed its due diligence, it will then take the opportunity to British Patient Capital’s investment committee.
e. Final Decision by Investment Committee. British Patient Capital’s investment committee will then decide whether to invest in the company.

FF:B will be delivered via British Patient Capital, a commercial subsidiary of the British Business Bank. Therefore, investment decisions will be made by the British Patient Capital Investment Committee. The Investment Committee will consider the extent to which investment proposals meet the FF:B programme’s policy and commercial objectives.

Any FF:B investment should not result in HMG owning more than 49% of any company (including when combining shareholdings from other investment programmes).

Some of the FF:B allocation is reserved for follow-on investment. In considering a follow-on investment, British Patient Capital will initially look to the lead investor to make a proposal but will make its own commercial investment decision.

Yes, as long at both parties meet the investment criteria above and the company is eligible for FF:B investment.

The timeframe will be determined by the nature of the transaction and speed of the lead investor.

There are no pre-determined FF:B specific restrictions on the use of proceeds although we would expect these to form part of the agreement between the company and the investors.

Regionality & Diversity

FF:B will be open to companies in all regions and nations of the UK.

The British Business Bank has regional finance products that aim to address regional imbalances in access to finance across the UK. For instance, the Northern Powerhouse Investment Fund, Midlands Engine Investment Fund and Cornwall and Isles of Scilly Investment Fund have invested over £339m between them into businesses in the North, Midlands, and Cornwall & the Isles of Scilly. Further information on these programmes can be accessed via the British Business Bank website.

The Bank has also invested over £23m alongside business angels through the Regional Angels Programme

The British Business Bank’s Finance Hub also provides information on funding available within each region and nation of the UK.